

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

526-mel

RRID:CVCL_8051

Type: Cell Line

Proper Citation

RRID:CVCL_8051

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_8051

Proper Citation: RRID:CVCL_8051

Description: Cell line 526-mel is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Sex unspecified

Disease: Melanoma

Defining Citation: [PMID:8027550](#), [PMID:8081556](#), [PMID:8537970](#), [PMID:9598804](#), [PMID:9670966](#), [PMID:10048982](#), [PMID:15467732](#), [PMID:18172304](#), [PMID:21857157](#)

Comments: From: Rosenberg, Steven A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: 526-mel

Synonyms: 526-MEL, 526 mel, 526mel, 526MEL, 526, MEL-526, Mel526, MEL526

Cross References: cancercelllines:CVCL_8051, CGH-DB:9297-4, Cosmic:905211, Cosmic:1303043, GEO:GSM206440, GEO:GSM218052, Progenetix:CVCL_8051, Wikidata:Q54603719

ID: CVCL_8051

Record Creation Time: 20220427T215055+0000

Record Last Update: 20260905T184330+0000

Ratings and Alerts

No rating or validation information has been found for 526-mel.

No alerts have been found for 526-mel.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Wang Y, et al. (2026) Efficient generation of human cDC1-like cells to detect and enhance tumor-reactive T cells via CD4+ T cell help. *Cell reports methods*, 101533.

Li Z, et al. (2025) Cell-surface RNA forms ternary complex with RNA-binding proteins and heparan sulfate to recruit immune receptors. *Molecular cell*, 85(24), 4633.

Dong B, et al. (2024) NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs. *Cancer immunology research*, 12(10), 1421.

Teppert K, et al. (2023) Combining CSPG4-CAR and CD20-CCR for treatment of metastatic melanoma. *Frontiers in immunology*, 14, 1178060.

Wenthe J, et al. (2023) Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models. *Journal of translational medicine*, 21(1), 506.

Sarén T, et al. (2023) Complementarity-determining region clustering may cause CAR-T cell dysfunction. *Nature communications*, 14(1), 4732.

Dolton G, et al. (2023) Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy. *Cell*, 186(16), 3333.

Margolis N, et al. (2022) Adenosine-Deaminase-Acting-on-RNA-1 Facilitates T-cell Migration toward Human Melanoma Cells. *Cancer immunology research*, 10(9), 1127.

Creelan BC, et al. (2021) Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. *Nature medicine*, 27(8), 1410.